RBCC: New Rainbow BioSciences Website Highlights Impressive Deal Flow
NOKOMIS, Fla.--(BUSINESS WIRE)-- Last week, Rainbow BioSciences, the biotechnology division of Rainbow Coral Corp. (OTCBB: RBCC), unveiled a new website highlighting its explorations into the multi-billion-dollar drug delivery and genome-mapping market.
To view the new website, please visit www.rainbowbiosciences.com.
In particular, the revamped site details the company's new partnership with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before. Some experts believe that the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to $81.5 billion by 2015.
In addition, RBCC is close to partnering with a cutting-edge genome-mapping facility in Houston capable of helping doctors assess genetic variations in patients in order to create more effective, optimized drug treatment plans. The genetic testing sector is one of the fastest-growing segments of the global biotech industry, with some market experts expecting it to reach $2.2 billion by 2017.
"The partnerships that we're targeting could help usher in a new era of healthcare: personalized medicine," said RBCC CEO Patrick Brown. "We see big growth in store for this sector, and Rainbow BioSciences' improved website will help us keep shareholders, potential investors and other interested parties up to date on our latest activities to bring these revolutionary technologies to a pharmacy or clinic near you."
Rainbow BioSciences is dedicated to developing and marketing new medical and research technologies to compete in a fast-growing industry alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Valeant Pharmaceuticals International (NYS: VRX) .
For more information on these initiatives, please visit www.rainbowbiosciences.com/investors.html.
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
KEYWORDS: United States North America Florida Texas
The article RBCC: New Rainbow BioSciences Website Highlights Impressive Deal Flow originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.